EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Efficacy and Safety of Keverprazan–Amoxicillin Dual Regimen in Initial Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial

Shanshan Wei iD, Zhihao Huang iD, Huizhen Xiong iD, Ji Wu iD, Dihua Mei iD, Jing Zhao iD, Wei Liu iD, Qingyun Liu iD, Yu Lin iD, Fang Liu iD, Xiang Peng iD, Honglei Chen iD

Helicobacter · 2026

DOI: 10.1111/hel.70100 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2026. Verfasst von Shanshan Wei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Endoscopy Center, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Amoxicillin, Anti-Bacterial Agents, Helicobacter pylori. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Futian Healthcare Research Project, Sun Yat-sen Eighth Affiliated Hospital Clinical Research Program, Shenzhen Nanshan District Health Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The efficacy of keverprazan–amoxicillin dual therapy (KA) in the treatment of Helicobacter pylori ( H. pylori ) has not yet been demonstrated. Here, we aimed to compare the eradication rate of the KA regimen with esomeprazole‐based bismuth quadruple therapy (EBQT) containing amoxicillin and clarithromycin for H. pylori initial eradication in the Chinese population.

Methods

Patients aged between 18–75 years were randomly assigned into KA group or the EBQT group. The KA group patients received keverprazan 20 mg (b.i.d.) and amoxicillin 1.0 g (t.i.d.) for 14 days. The EBQT group patients took esomeprazole 20 mg (b.i.d.), amoxicillin 1.0 g (b.i.d.), clarithromycin 0.5 g (b.i.d.), and bismuth potassium citrate 220 mg (b.i.d.) for 14 days. The primary outcome was the H. pylori eradication rate 28 days after therapy. Secondary outcomes included compliance and adverse events.

Results

A total of 394 patients were enrolled in this study. Eradication rates in the KA group and the EBQT group were 87.88% and 84.18% in intention‐to‐treat analysis (ITT) (rate difference: 3.70%, 95% CI: −3.14% to 10.53%), 92.55% and 88.24% in modified ITT analysis (rate difference: 4.32%, 95% CI: −1.63% to 10.27%), and 93.99% and 90.56% in per‐protocol analysis (PP) (rate difference: 3.43%, 95% CI: −2.05% to 8.92%), respectively. The eradication rates for the KA group were not inferior to those of the EBQT group in ITT, modified ITT, and PP analysis. The incidences of nausea and overall adverse effects in the KA group were significantly lower than those of the EBQT group.

Conclusions

Keverprazan 20 mg twice daily with high‐dose amoxicillin demonstrates a noninferior efficacy to bismuth quadruple therapy for initial H. pylori eradication. Trial Registration Chinese Clinical Trial Registry, registration No: ChiCTR2400092511

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsAmoxicillinAnti-Bacterial AgentsHelicobacter pyloriHumansMiddle AgedAdultDrug Therapy, CombinationFemaleTreatment OutcomeMaleAdolescentYoung AdultAgedChinaEsomeprazoleClarithromycin

Stichwörter der Autor:innen

Helicobacter pyloriadverse eventinitial eradicationkeverprazanrandomized controlled trial

Substanzen

AmoxicillinAnti-Bacterial AgentsEsomeprazoleClarithromycin

Autor:innen und Institutionen

  • Gastrointestinal Endoscopy Center, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
  • Department of Gastroenterology, Puning Overseas Chinese Hospital, Puning, China.
  • Department of Gastroenterology, Foshan Fosun Chancheng Hospital, Foshan, China.
  • Gastrointestinal Endoscopy Center, Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, China.
  • Department of Prevention and Health Care, Southern University of Science and Technology Hospital, Shenzhen, China.
  • Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

ORCID-Profile: Shanshan Wei, Zhihao Huang, Huizhen Xiong, Ji Wu, Dihua Mei, Jing Zhao, Wei Liu, Qingyun Liu, Yu Lin, Fang Liu, Xiang Peng, Honglei Chen

Förderung

  • Futian Healthcare Research Project
  • Sun Yat-sen Eighth Affiliated Hospital Clinical Research Program
  • Shenzhen Nanshan District Health Science and Technology Program

Zitieren

APA

Wei, S., Huang, Z., Xiong, H., Wu, J., Mei, D., Zhao, J., Liu, W., Liu, Q., Lin, Y., Liu, F., Peng, X., & Chen, H. (2026). Efficacy and Safety of Keverprazan–Amoxicillin Dual Regimen in Initial Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter. https://doi.org/10.1111/hel.70100

Vancouver

Wei S, Huang Z, Xiong H, Wu J, Mei D, Zhao J, et al. Efficacy and Safety of Keverprazan–Amoxicillin Dual Regimen in Initial Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter. 2026. doi:10.1111/hel.70100

BibTeX
@article{Wei2026,
  author = {Wei, Shanshan and Huang, Zhihao and Xiong, Huizhen and Wu, Ji and Mei, Dihua and Zhao, Jing and Liu, Wei and Liu, Qingyun and Lin, Yu and Liu, Fang and Peng, Xiang and Chen, Honglei},
  title = {Efficacy and Safety of Keverprazan–Amoxicillin Dual Regimen in Initial Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial},
  journal = {Helicobacter},
  year = {2026},
  doi = {10.1111/hel.70100}
}
Kostenlos starten →